Jeffrey Rothman
Endocrinology, Diabetes & Metabolism · Staten Island, NYNPI 1811982812
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 288 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 20.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $1,216 and has fallen 92.2% since, to $95 in 2024.
Across 288 payments — averaging $18.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Amgen$665
- AstraZeneca$516
- AbbVie$477
- Abbott$408
- Amneal Pharmaceuticals LLC$331
- plus $2K from 24 others
Across 167 payments — averaging $1387.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$109K
- CSL Behring$62K
- Sanofi US Services Inc.$41K
- Takeda Pharmaceuticals U.S.A., Inc.$13K
- Shire North American Group Inc$7K
What the payments were for
- Food & beverage$5,191100%
- Education$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 65 | $1,040 |
| Amgen | 37 | $665 |
| AstraZeneca | 26 | $516 |
| AbbVie | 29 | $477 |
| Abbott | 18 | $408 |
| Amneal Pharmaceuticals LLC | 15 | $331 |
| Radius Health, Inc. | 14 | $320 |
| Merck | 16 | $249 |
| Lilly USA, LLC | 9 | $223 |
| Medtronic(2 entities) | 10 | $170 |
| Johnson & Johnson | 14 | $150 |
| Dexcom, Inc. | 6 | $119 |
| Mannkind Corporation | 6 | $104 |
| Sanofi-aventis U.S. LLC | 3 | $55 |
| Bristol Myers Squibb | 1 | $53 |
| Ascendis Pharma Endocrinology Inc | 2 | $43 |
| Corcept Therapeutics | 2 | $39 |
| Boehringer Ingelheim | 2 | $32 |
| Cequr Corporation | 2 | $28 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Amryt Pharma Holdings Ltd | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Amphastar Pharmaceuticals, Inc. | 1 | $19 |
| Bayer | 1 | $17 |
| Tolmar, Inc. | 1 | $16 |
| Vistapharm, Inc. | 1 | $15 |
| IBSA Pharma Inc. | 1 | $15 |
| Lifescan, Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Advanced Oxygen Therapy Inc. | 1 | $14 |
How this compares
$5,210 in reported general payments places this provider in the 75th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 18 | $26,014 |
| FarxigaDapagliflozin Propanediol | 11 | $15,001 |
| SynthroidLevothyroxine Sodium | 66 | $5,632 |
| Levothyroxine Sodium | 91 | $1,317 |
| Metformin Hcl | 33 | $418 |
| Rosuvastatin Calcium | 21 | $412 |
| Atorvastatin Calcium | 33 | $392 |
| Ezetimibe | 13 | $381 |
| Losartan Potassium | 12 | $314 |
| Glimepiride | 17 | $241 |
| Simvastatin | 27 | $215 |
| Amlodipine Besylate | 13 | $199 |
| Alendronate Sodium | 20 | $135 |
| Metformin Hcl ErMetformin Hcl | 11 | $128 |
| Lisinopril | 17 | $126 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $223 | $26,01418 claims |
| AstraZenecaFarxiga | $516 | $15,00111 claims |
| AbbVieSynthroid | $477 | $5,63266 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $331 | $1,31791 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in Staten Island
- Philip OtterbeckStaten Island$575K
- Shahed QuyyumiStaten Island$154K
- Robert BuschAlbany$2.7M
- Michael ShanikSmithtown$1.2M
- Ajay ChaudhuriBuffalo$888K
- Vinay KapoorManhasset$820K
- John BilezikianNew York$809K
- Barbara HirschManhasset$746K
- Martin GrajowerBronx$713K
- Anastasios ManessisNew York$656K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.